Skip to main content
Premium Trial:

Request an Annual Quote

GenTel, Abnova to Co-develop Custom Immunoassays

NEW YORK, Nov. 9 (GenomeWeb News) - Gentel will combine its custom multiplex immunoassay development service with Abnova's high-throughput protein and antibody content-manufacturing capabilities, Gentel Biosurfaces said today.

 

GenTel's PATH Protein MicroArray System is based on ultra-thin nitrocellulose surface chemistry developed specifically for antibody arrays.

 

GenTel, which is privately held, will develop and offer multiplex immunoassays using protein content from Abnova, the company said.

 

Taiwan-based Abnova specializes in high throughput, in vitro wheat germ protein expression and monoclonal antibody production.

 

Financial details were not disclosed.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.